A securities fraud class action notice highlights potential liability for Capricor Therapeutics and invites affected investors to seek lead plaintiff status
Executive summary: Investors who purchased Capricor Therapeutics (CAPR) shares between December 17, 2025 and July 26, 2026 were notified of an opportunity to serve as lead plaintiff in a securities fraud class action lawsuit announced by Kessler Topaz Meltzer & Check LLP. The lawsuit could result in financial liability for Capricor Therapeutics, affect its share price, and signal heightened regulatory oversight of biotech disclosures.
Who is involved: Capricor Therapeutics, Inc., its shareholders, and the law firm Kessler Topaz Meltzer & Check LLP are the primary parties.
Likely next: Plaintiffs will file a motion for lead plaintiff status before the court‑set deadline, after which the case may proceed to class certification and potential settlement negotiations.
The press release issued by Kessler Topaz Meltzer & Check LLP informs investors that they may seek appointment as lead plaintiff in a class action alleging securities fraud involving Capricor Therapeutics shares traded between December 2025 and July 2026. The notice does not detail the alleged misconduct but specifies the class period and the deadline for lead plaintiff motions. Such litigation can impose costs on the company and influence investor sentiment. The outcome will depend on court rulings regarding class certification and any eventual settlement.
Timeline
- — ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP (PR Newswire)
- — GPGI, Inc. (NYSE: GPGI) Class Action Lawsuit Seeks Recovery for Investors; September 14, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP (PR Newswire)
Analysis — what this means
Sectors affected
Historical parallels
- GPGI class action lawsuit filed August 20, 2026, announced by Kessler Topaz Meltzer & Check LLP
Contradictions
- Title states ImmunityBio, Inc. (IBRX) as subject; excerpt states Capricor Therapeutics, Inc. (NASDAQ: CAPR) as subject.
Key entities
Sources
Open the full interactive case file on Beyond →